1. Pink Sheet
  2. >>Geography
  3. >>Europe

New UK Rules On Supplementary Protection Certificates – Will You Be Affected?

 
• By Ian Schofield

Companies are being encouraged to look at whether they will be impacted by new UK rules on supplementary protection certificates that come into effect from the beginning of next year.

Brexit broken egg
Brexit has required changes to the SPC rules in the UK (Shutterstock)

The UK Intellectual Property Office (IPO) has published details of the new legislation on supplementary protection certificates that will come into force on 1 January 2025 and may require companies to take action, particularly where the SPC is at least partially supported by a centralized EU marketing authorization.

The new legislation was drawn up to implement certain provisions of the Windsor Framework, under which the UK drugs regulator, the MHRA, will next year...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Legal & IP

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 
• By Eliza Slawther

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.